Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 16.78%115.59B | 9.88%420.31B | 15.85%107.86B | 1.04%105.17B | 15.82%108.29B | 7.78%98.99B | 5.40%382.54B | 11.65%93.1B | 11.98%104.09B | -1.40%93.49B |
Cost of revenue | 18.39%15.52B | -1.98%58.71B | 19.56%15.03B | -40.30%11.52B | 36.18%19.05B | -6.63%13.11B | -6.31%59.9B | 22.02%12.57B | 18.80%19.3B | -29.24%13.99B |
Gross profit | 16.53%100.08B | 12.08%361.6B | 15.27%92.83B | 10.45%93.65B | 12.24%89.24B | 10.38%85.88B | 7.90%322.64B | 10.18%80.53B | 10.53%84.79B | 5.93%79.51B |
Operating expense | 8.72%62.01B | 6.31%242.78B | 5.83%67.23B | 6.35%59.43B | 6.55%59.09B | 6.24%57.04B | 2.62%228.37B | -8.26%63.52B | 7.73%55.88B | 7.84%55.45B |
Selling and administrative expenses | 8.72%62.01B | 6.31%242.78B | 5.83%67.23B | 6.35%59.43B | 6.55%59.09B | 6.24%57.04B | 2.62%228.37B | -8.26%63.52B | 7.73%55.88B | 7.84%55.45B |
-General and administrative expense | 8.72%62.01B | 6.31%242.78B | 5.83%67.23B | 6.35%59.43B | 6.55%59.09B | 6.24%57.04B | 2.62%228.37B | -8.26%63.52B | 7.73%55.88B | 7.84%55.45B |
Operating profit | 31.98%38.06B | 26.05%118.83B | 50.52%25.61B | 18.38%34.23B | 25.35%30.15B | 19.61%28.84B | 23.27%94.27B | 342.33%17.01B | 16.37%28.91B | 1.78%24.05B |
Net non-operating interest income (expenses) | -54.47%-7.83B | -63.18%-24.9B | -62.66%-7.39B | -76.12%-6.62B | -52.24%-5.81B | -61.74%-5.07B | -33.12%-15.26B | -45.39%-4.55B | -35.25%-3.76B | -29.48%-3.82B |
Non-operating interest expense | 54.47%7.83B | 63.18%24.9B | 62.66%7.39B | 76.12%6.62B | 52.24%5.81B | 61.74%5.07B | 33.12%15.26B | 45.39%4.55B | 35.25%3.76B | 29.48%3.82B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 301.05%381M | 572.09%289M | 160.47%112M | 54M | 27M | 95M | 43M | 43M | 0 | 0 |
Income from associates and other participating interests | 65.32%2.58B | 389.17%29.26B | 277.79%2.84B | 162.29%3.37B | 1,037.37%21.49B | -23.87%1.56B | 30.38%5.98B | -41.75%752M | -13.52%1.29B | 494.03%1.89B |
Special income (charges) | -48.60%-12.23B | -10.62%-38.29B | 29.83%-11.2B | -27.77%-8.08B | -71.77%-10.78B | -35.92%-8.23B | -40.84%-34.61B | -158.38%-15.96B | -13.77%-6.32B | -10.30%-6.28B |
Less:Write off | 48.60%12.23B | 10.62%38.29B | -29.83%11.2B | 27.77%8.08B | 71.77%10.78B | 35.92%8.23B | 40.84%34.61B | 158.38%15.96B | 13.77%6.32B | 10.30%6.28B |
Other non-operating income (expenses) | -61.70%2.61B | 20.15%12.76B | 664.34%4.21B | -67.14%1.45B | -85.15%291M | 31.40%6.81B | 116.25%10.62B | -516.53%-746M | 48.08%4.4B | 66.02%1.96B |
Income before tax | -1.80%23.58B | 60.46%97.95B | 511.64%14.18B | -0.49%24.4B | 98.59%35.36B | 8.36%24.01B | 22.24%61.04B | 19.66%-3.44B | 16.94%24.52B | 7.97%17.81B |
Income tax | -2.94%6.76B | 43.55%24.67B | 282.57%3.29B | -6.50%6.19B | 51.17%8.23B | 0.55%6.97B | 19.80%17.18B | 50.81%-1.8B | 2.72%6.62B | -10.98%5.44B |
Net income | -1.33%16.82B | 67.08%73.29B | 763.09%10.89B | 1.73%18.22B | 119.46%27.14B | 11.91%17.04B | 23.23%43.86B | -163.56%-1.64B | 23.25%17.91B | 19.13%12.37B |
Net income continuous operations | -1.33%16.82B | 67.08%73.29B | 763.09%10.89B | 1.73%18.22B | 119.46%27.14B | 11.91%17.04B | 23.23%43.86B | -163.56%-1.64B | 23.25%17.91B | 19.13%12.37B |
Noncontrolling interests | 141.76%220M | 14.18%298M | -255.56%-42M | 22.46%169M | 77.27%78M | 78.43%91M | 19.72%261M | 164.29%27M | 7.81%138M | -30.16%44M |
Net income attributable to the company | -2.09%16.6B | 67.41%72.99B | 754.88%10.93B | 1.56%18.05B | 119.62%27.06B | 11.68%16.95B | 23.25%43.6B | -187.76%-1.67B | 23.39%17.77B | 19.44%12.32B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -2.09%16.6B | 67.41%72.99B | 754.88%10.93B | 1.56%18.05B | 119.62%27.06B | 11.68%16.95B | 23.25%43.6B | -187.76%-1.67B | 23.39%17.77B | 19.44%12.32B |
Gross dividend payment | ||||||||||
Basic earnings per share | -5.79%102.15 | 62.44%453.08 | 721.54%66.38 | -2.74%110.56 | 112.52%167.51 | 11.66%108.43 | 23.23%278.92 | -187.10%-10.68 | 23.37%113.67 | 19.41%78.82 |
Diluted earnings per share | -5.86%102.04 | 62.40%452.69 | 719.57%66.17 | -2.65%110.49 | 112.78%167.44 | 11.80%108.39 | 23.27%278.75 | -181.05%-10.68 | 23.28%113.5 | 19.28%78.69 |
Dividend per share | 0 | 21.43%85 | 21.43%85 | 0 | 0 | 0 | 27.27%70 | 27.27%70 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |